Business Context and Reporting Period
This Form 8-K Current Report was filed by American Brivision (Holding) Corporation on September 20, 2017, regarding events that occurred on September 15, 2017. The filing details significant changes to the Company's executive leadership, including the resignation of the CEO, CFO, and Chief Scientific Officer, and the immediate appointment of successors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
The Company underwent a complete turnover of its top three executive officers effective September 15, 2017:
- CEO and President: Eugene Jiang resigned but remains Chairman of the Board. Dr. Howard Doong was appointed as the new CEO and President.
- CFO, Secretary, and Treasurer: Kira Huang resigned and will remain as a consultant. Mr. Chun Mu Hung was appointed to fill the vacancy.
- Chief Scientific Officer (CSO): (Frank) Chih-Chung Liu resigned from the subsidiary American BriVision Corporation but remains a researcher. Dr. Chi-Hsin Richard King was appointed as the new CSO.
Guidance, Outlook, and Risks
Management Commentary and Compensation: The Company entered into new employment agreements with the incoming executives. Key terms include:
- Dr. Howard Doong (CEO): Annual base salary of $100,000. He commits to at least 10 hours per week. Severance of 12 months' base salary applies if terminated without cause or if he resigns due to material changes in duties/salary.
- Mr. Chun Mu Hung (CFO): Annual base salary of $40,000. Similar severance terms apply (12 months' base salary).
- Dr. Chi-Hsin Richard King (CSO): Annual base salary of $50,000. Similar severance terms apply (12 months' base salary).
- Conflict of Interest: Dr. Doong concurrently serves as CEO/CSO for LifeCode Biotechnology and Wuhan Frasergen Genomic Medicine. The filing notes a potential conflict of interest if these entities compete with the Company, though Dr. Doong asserts their business focuses differ (cancer diagnosis and DNA sequencing vs. the Company's translational medicine and global market exploitation).
- Transition Risk: The immediate resignation of three key officers creates a transition period, though the outgoing CFO has agreed to assist as a consultant.
Investor Verification Checklist
- Verify the extent of Dr. Doong's time commitment (10 hours/week) and how this impacts strategic execution.
- Review the specific business scopes of LifeCode Biotechnology and Wuhan Frasergen Genomic to assess the actual risk of competition with American Brivision.
- Confirm the Company's current cash position to ensure it can meet the new annual salary obligations ($190,000 total) and potential severance liabilities.
- Check for any pending financial reports (10-K or 10-Q) to understand the financial context of this leadership change.